Mitral regurgitation (MR) is the most common heart valve disorder in the US, with over 4 million individuals affected globally and an incidence of over 250,000 annually. Results of severe MR frequently lead to shortness of breath and fatigue and to potential heart failure and death without treatment. Open heart surgical Mitral valve repair (OHMVR), is the gold-standard option to restore the valve function and patient prognosis. Today minimally-invasive options (transcatheter therapy, TMVR) allow surgeons and interventional cardiologists to perform valvular repairs without opening a patient's chest and represent a safe alternative in a subset of frail patients. The MitralPrint device will be the first endovascular, piezoresistive pressure sensor designed to quantify myocardial contraction fraction (MCF) in real-time during both OHMVR and TMVR allowing the surgeon to record an objective parameter on the MR. This eliminates the need for subjective trans-thoracic ultrasound assessment.